Table 6.
Summary of effects of immunosuppressive therapy and other risk factors on SARS-CoV-2 infection and severe COVID-19 in vaccinated and unvaccinated patients15.
| Independent risk factor yes/no | SARS-CoV-2 infection (pre-vaccination) | Severe COVID-19 (pre-vaccination) | No humoral vaccine response (after 3rd dose) | SARS-CoV-2 Infection (post-vaccination) | Severe COVID-19 (post-vaccination) |
|---|---|---|---|---|---|
| Corticosteroids (methylprednisone) | No | Yes | Yes | Yes | Yes |
| Mycophenolate | No | No | Yes | No | Yes |
| Tacrolimus | No | No | No | No | No |
| Cyclosporin | No | No | No | No | No |
| Everolimus | No | No | No | No | No |
| Azathioprine | No | No | No | No | No |
| Other risk factors | Close contact with COVID-19 patient, diabetes and lung disease | Housemate with confirmed COVID-19, chronic kidney disease, hypertension | Older age, chronic kidney disease | Younger age, shorter interval to transplantation, and only 1 vaccination dose | Older age |